The board of directors of Shanghai Henlius Biotech, Inc. announced that Dr. Scott Shi-Kau Liu ("Dr. LIU") has tendered his resignation from the position as an executive director, a member of the strategy committee of the Board, a member of the environmental, social and governance committee with effect from 30 September 2020 due to a change in personal business priorities. After resignation, Dr. LIU will serve as the head of strategic advisory committee of the company, focusing on the directions of the company's research and development works, the formulation of the company's strategies, and the team construction and development of the company. The Board also announced that Mr. Wenjie Zhang has been nominated as an executive director of the second session of the Board, subject to the approval of the Shareholders at an extraordinary general meeting of the company. Mr. ZHANG, as the chief executive officer and the president of the company, will lead the senior management team on the company's day-to-day management and oversee the operation of the company and its subsidiaries (the "Group"). Mr. ZHANG has been the senior vice president, chief commercial operation officer and chief strategy officer of the company from March 2019 to February 2020, and has served as the president of the company, the president of Shanghai Henlius Biopharmaceutical Co. Ltd. and Shanghai Henlius Biologics Co. Ltd., since February 2020.